Tech Company Financing Transactions
Elucida Oncology Funding Round
Elucida Oncology closed a $44 million Series A venture capital round on 1/13/2021. Investors included private investors.
Transaction Overview
Company Name
Announced On
1/13/2021
Transaction Type
Venture Equity
Amount
$44,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the financing will be used to complete IND enabling studies for the company's lead CDC program, expand the management team and laboratory capabilities, and generate additional pre-clinical efficacy data in several tumor models.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Deer Park Dr. E
Monmouth Junction, NJ 08852
USA
Monmouth Junction, NJ 08852
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Elucida is a Proud Licensee and Research Partner of Memorial Sloan Kettering Cancer Center. Elucida is a Proud Licensee and Research Partner of Cornell University. Elucida has an Ongoing Partnership with the MSKCC-Cornell Center for Translation of Nanomedicines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Geno Germano
Chief Medical Officer
Eliel Bayever
Chief Scientific Officer
Gregory Adams
Chief Technical Officer
Kai Ma
Vice President
Aranapakam Venkatesan
VP - Operations
Paul Rudick
Browse more venture capital transactions:
Prev: 1/13/2021: Outer venture capital transaction
Next: 1/13/2021: Gro Intelligence venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs